首页 | 本学科首页   官方微博 | 高级检索  
检索        


Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia
Authors:Kotaro Arita  Takeshi Kondo  Junichi Sugita  Akio Shigematsu  Souichi Shiratori  Kentaro Wakasa  Atsushi Yasumoto  Makoto Ibata  Yusuke Shono  Misato Kikuchi  Hideki Goto  Yukari Takeda  Mutsumi Takahata  Naoko Kato  Mitsufumi Nishio  Shuichi Ota  Junji Tanaka  Masahiro Imamura
Institution:Stem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan. arita-tym@umin.ac.jp
Abstract:The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m(2) for 3 days, VCR 1.4 mg/m(2) for 1 day, and PSL 60 mg/m(2) for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1,055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号